Momentum

Relative Strength (%)
1m+12.68%
3m
6m
1yr
Volume Change (%)
10d/3m
Price vs... (%)
52w High-53.72%
50d MA
200d MA

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st May 202231st May 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Cell MedX EPS forecast chart

Profile Summary

Cell MedX Corp. is a development-stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases, such as diabetes, by developing technologies to help manage the illness and related complications. The Company, through its subsidiary, Avyonce Cosmedics Inc. (Avyonce), is engaged in reselling and marketing spa technology and equipment to the beauty and wellness industry. Avyonce is involved in carrying out observational studies using eBalance Technology. The eBalance Technology is used for the use of micro currents for the treatment of diabetes and related ailments. Avyonce also provides continuing education to the estheticians and healthcare professionals in the field of medical aesthetics. The Company is engaged in developing a family of devices based on the eBalance Technology.

Directors

Last Annual
May 31st, 2021
Last Interim
August 31st, 2021
Incorporated
March 19th, 2010
Public Since
March 11th, 2013
No. of Employees
0
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
62,923,063
Blurred out image of a map
Address
123 W Nye Ln Ste 446, CARSON CITY, 89706-0899
Web
http://cellmedx.com/
Phone
+1 3105089398
Auditors
Dale Matheson Carr-Hilton LaBonte LLP

CMXC Share Price Performance

Upcoming Events for CMXC

Similar to CMXC

Picture of Acura Pharmaceuticals logo

Acura Pharmaceuticals

us flag iconPink Sheets on Nasdaq

Picture of Adhera Therapeutics logo

Adhera Therapeutics

us flag iconPink Sheets on Nasdaq

Advantis

us flag iconPink Sheets on Nasdaq

Picture of Adynxx logo

Adynxx

us flag iconPink Sheets on Nasdaq

Picture of Aeolus Pharmaceuticals logo

Aeolus Pharmaceuticals

us flag iconPink Sheets on Nasdaq

FAQ

Or unlock with your email

Or unlock with your email